EASi-PROKTK

Vicadrostat for the prevention of cardiovascular events in patients with hypertension, diabetes, and other comorbidities.

A double-blind, randomized, phase III parallel-group study to evaluate the efficacy and safety of the combination of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, arterial hypertension, and established cardiovascular disease. 

Book
examination